Literature DB >> 35836088

Pretreatment [18F]FDG PET/CT and MRI in the prognosis of nasopharyngeal carcinoma.

Amina Gihbid1,2, Ghofrane Cherkaoui Salhi3, Imane El Alami1, Hasnaa Belgadir4, Nezha Tawfiq5, Karima Bendahou5, Mohammed El Mzibri6, Rachida Cadi2, Naima El Benna4, Amal Guensi3, Meriem Khyatti7.   

Abstract

OBJECTIVE: The present study aimed to assess the prognostic interest of metabolic and anatomic parameters derived from 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) and head and neck magnetic resonance imaging (HN-MRI) for better management of nasopharyngeal carcinoma (NPC).
METHODS: In this study, pre-treatment [18F]FDG PET/CT and HN-MRI parameters of NPC patients diagnosed between January 2017 and December 2018, were prospectively investigated. Correlation between those parameters and 4-year patient's survival outcomes was evaluated using Kaplan-Meier and Cox-regression analyses.
RESULTS: Our results revealed a significant association between pre-treatment nodal-maximum standardized uptake value (N-SUV max) and N categories (p = 0.01), between pre-treatment node-to-tumor SUV ratio (NTR) and both tumor size (p = 0.01) and N categories (p = 0.009), as well as between metabolic tumor volume (MTV) and both tumor size and NPC overall stage (p < 0.000). In multivariate analyses, pre-treatment N-SUV max, NTR and MTV were significant independent predictors of overall survival, distant metastasis-free survival, and progression-free survival (PFS) (p < 0.05). N-SUV max and MTV were also found to be significant independent predictors of loco-regional recurrence-free survival (p < 0.05), whereas HN-MRI detection of skull-base bone invasion was an independent factor associated with worse PFS in NPC (p = 0.03).
CONCLUSIONS: The present study highlights N-SUV max, NTR and MTV derived from [18F]FDG PET/CT, and skull-base bone invasion defined by HN-MRI, as promising metabolic and anatomic prognosis biomarkers for NPC.
© 2022. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.

Entities:  

Keywords:  HN-MRI; Nasopharyngeal carcinoma; Prognosis; [18F]FDG PET/CT

Mesh:

Substances:

Year:  2022        PMID: 35836088     DOI: 10.1007/s12149-022-01770-4

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.258


  34 in total

1.  [Influence of MRI on the T, N staging system of nasopharyngeal carcinoma].

Authors:  Chuanmiao Xie; Biling Liang; Haogao Lin; Peihong Wu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2002-03

Review 2.  Focus on nasopharyngeal carcinoma.

Authors:  Kwok Wai Lo; Ka Fai To; Dolly P Huang
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

3.  Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P Bossi; A T Chan; L Licitra; A Trama; E Orlandi; E P Hui; J Halámková; S Mattheis; B Baujat; J Hardillo; L Smeele; C van Herpen; A Castro; J-P Machiels
Journal:  Ann Oncol       Date:  2020-12-25       Impact factor: 32.976

4.  [Evaluation of CT, MRI and PET-CT in detecting retropharyngeal lymph node metastasis in nasopharyngeal carcinoma].

Authors:  Yong Su; Chong Zhao; Chuan-Miao Xie; Li-Xia Lu; Ying Sun; Fei Han; Hu-Bing Wu; Nian-Ji Cui; Zong-Yuan Zeng; Tai-Xiang Lu
Journal:  Ai Zheng       Date:  2006-05

Review 5.  Magnetic resonance imaging of nasopharyngeal carcinoma.

Authors:  Eugene Yu; Brian O'Sullivan; John Kim; Lillian Siu; Eric Bartlett
Journal:  Expert Rev Anticancer Ther       Date:  2010-03       Impact factor: 4.512

6.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

7.  Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience.

Authors:  Anne W M Lee; W M Sze; Joseph S K Au; S F Leung; T W Leung; Daniel T T Chua; Benny C Y Zee; Stephen C K Law; Peter M L Teo; Stewart Y Tung; Dora L W Kwong; W H Lau
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

Review 8.  Nasopharyngeal carcinoma.

Authors:  Melvin L K Chua; Joseph T S Wee; Edwin P Hui; Anthony T C Chan
Journal:  Lancet       Date:  2015-08-28       Impact factor: 79.321

9.  Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up.

Authors:  Shu-Hang Ng; Sheng-Chieh Chan; Tzu-Chen Yen; Joseph Tung-Chieh Chang; Chun-Ta Liao; Sheung-Fat Ko; Feng-Yuan Liu; Shu-Chyn Chin; Kang-Hsing Fan; Cheng-Lung Hsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

10.  Extension of local disease in nasopharyngeal carcinoma detected by magnetic resonance imaging: improvement of clinical target volume delineation.

Authors:  Shao-Bo Liang; Ying Sun; Li-Zhi Liu; Yong Chen; Lei Chen; Yan-Ping Mao; Ling-Long Tang; Li Tian; Ai-Hua Lin; Meng-Zhong Liu; Li Li; Jun Ma
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-27       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.